SCHEMBL1266356

SCHEMBL1266356

O=S(=O)(/C=C/C1CC1)N1CCc2ccccc2C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.63
MEN1 O00255 5/20 0.63
L3MBTL1 Q9Y468 2/20 0.50
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
USP30 Q70CQ3 1/20 0.44
AKR1C3 P42330 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
MCOLN2 Q8IZK6 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
MCOLN1 Q9GZU1 1/20 0.41
CYP3A4 P08684 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266358 1.00 KMT2A (0.63) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1265953 0.78 KMT2A (1.00) KMT2AMEN1L3MBTL1TSHRAKR1C3
SCHEMBL1265951 0.78 KMT2A (1.00) KMT2AMEN1L3MBTL1TSHRAKR1C3
SCHEMBL23917550 0.76 KMT2A (0.63) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1266709 0.75 KMT2A (0.51) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1266708 0.75 KMT2A (0.51) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1266609 0.74 KMT2A (0.68) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1266610 0.74 KMT2A (0.68) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1265962 0.73 KMT2A (0.67) KMT2AMEN1L3MBTL1TSHRMAPK1
SCHEMBL1265963 0.73 KMT2A (0.67) KMT2AMEN1L3MBTL1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951674-B1 SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES MERCK SERONO SA (CH) 2011-11-23 EP disclosed
US-7879876-B2 matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis MERCK SERONO SA (CH) 2011-02-01 US disclosed
US-20090221575-A1 Sulfonamide derivatives and use thereof for the modulation of metalloproteinases LABORATOIRES SERONO SA (CH) 2009-09-03 US disclosed
EP-1951674-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES LABORATOIRES SERONO S.A. (CH) 2008-08-06 EP disclosed
WO-2007048788-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES LABORATOIRES SERONO S.A. (CH) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221575-A1 Sulfonamide derivatives and use thereof for the modulation of metalloproteinases MMP12, STS, MMP14 KMT2A 1261/4885MEN1 3388/4885L3MBTL1 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.